EU Marketing Authorization Rejected for Bone Disorder Drug

French drugmaker Ipsen said on Wednesday the European Commission has not granted marketing authorization for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva.

Related Keywords

France ,French ,Dina Kartit ,Mike Harrison ,Metabolic Drugs Advisory Committee ,European Commission ,Drug Administration Endocrinologic ,Reuters ,European Union ,European Medicines Agency ,Medicinal Products ,Human Use ,Drug Administration ,